What were Pfizer’s (NYSE:PFE) second-quarter results?

Pfizer (NYSE:PFE) reported revenue of $15.03 billion, a net loss of $248 million and adjusted diluted EPS of $0.77. Revenue increased 3% year over year.

Why did Pfizer (NYSE:PFE) report a net loss?

Pfizer (NYSE:PFE) reported a $248 million net loss mainly because it recorded $4.3 billion in non-cash intangible-asset impairments. The total included $3.8 billion associated with sigvotatug vedotin and $525 million related to Oxbryta.

How did Eliquis perform for Pfizer (NYSE:PFE)?

Pfizer (NYSE:PFE) reported Eliquis sales of $2.43 billion, representing 19% operational growth, while cancer treatment Padcev grew 23% operationally.

What is Pfizer’s (NYSE:PFE) updated 2026 guidance?

Pfizer (NYSE:PFE) expects full-year revenue of $60.5–$62.5 billion, compared with its previous $59.5–$62.5 billion range. The company reaffirmed adjusted diluted EPS guidance of $2.80–$3.00.

What cost savings did Pfizer (NYSE:PFE) announce?

Pfizer (NYSE:PFE) announced another $2.5 billion in anticipated savings from productivity and manufacturing initiatives. The company expects those savings to be realised between 2027 and 2029.

Image for illustrative purposes only. Not a real photo.

Pfizer revenue shoots up 3% to $15 billion

Written by Heidi Cuthbert Published Aug 4, 2026, 1:12 PM

Pfizer reported second-quarter revenue of $15.03 billion, beating the $14.4 billion analyst estimate.
Pfizer shares were up 0.1% at $25.03 in premarket trading.
The company raised its 2026 revenue forecast and announced another $2.5 billion in expected cost savings.

Pfizer (NYSE:PFE) reported second-quarter revenue of $15.03 billion, up 3%, while adjusted diluted earnings reached $0.77 per share.

Revenue exceeded analysts’ $14.4 billion estimate, and adjusted EPS beat the $0.68 consensus despite slipping from $0.78 one year earlier.

Pfizer recorded a $248 million net loss after $4.3 billion in non-cash impairments, including $3.8 billion tied to sigvotatug vedotin.

Pfizer raised 2026 revenue guidance to $60.5–$62.5 billion and reaffirmed adjusted EPS of $2.80–$3.00.

Following the announcement, Pfizer's share price was up 0.1% at $25.03.

Eliquis sales rose 19% operationally to $2.43 billion and Padcev increased 23%, partly offsetting weaker Paxlovid and Comirnaty sales.

Pfizer said another $2.5 billion in productivity savings is expected from 2027 through 2029 as it invests in oncology and obesity treatments.

Pfizer revenue shoots up 3% to $15 billion

Frequently asked questions

Assets related to this article